Search research articles
Contact Us
Filters
Showing results (51-60 of 64) with videos related to
Page
of 7
Sort By:
Proceedings of the National Academy of Sciences of the United States of America
|
June 20, 1995
A paradigm for drug discovery employing encoded combinatorial libraries
J J Burbaum, M H Ohlmeyer, J C Reader, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 18, 2005
Guiding farnesyltransferase inhibitors from an ECLiPS library to the catalytic zinc
Chia-Yu Huang, Tara M Stauffer, Corey L Strickland, et al.
Journal of Combinatorial Chemistry
|
January 11, 2000
A statistical-based approach to assessing the fidelity of combinatorial libraries encoded with electrophoric molecular tags. Development and application of tag decode-assisted single bead LC/MS analysis
R E Dolle, J Guo, L O'Brien, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 22, 2010
Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinases
Thomas P Matthews, Tatiana McHardy, Suki Klair, et al.
Cancers
|
September 10, 2021
Malignant Ascites in Ovarian Cancer: Cellular, Acellular, and Biophysical Determinants of Molecular Characteristics and Therapy Response
Brittany P Rickard, Christina Conrad, Aaron J Sorrin, et al.
Molecular Cancer Therapeutics
|
January 8, 2010
The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106
Michael I Walton, Paul D Eve, Angela Hayes, et al.
Journal of Medicinal Chemistry
|
October 23, 2012
Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors
Michael Lainchbury, Thomas P Matthews, Tatiana McHardy, et al.
Cancers
|
February 15, 2022
Microtentacle Formation in Ovarian Carcinoma
Jocelyn C Reader, Cong Fan, Eleanor Claire-Higgins Ory, et al.
British Journal of Cancer
|
March 4, 2024
Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
Dana M Roque, Eric R Siegel, Natalia Buza, et al.
British Journal of Cancer
|
February 12, 2022
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
Dana M Roque, Eric R Siegel, Natalia Buza, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 64) with videos related to
Sort By:
Page
of 7
Proceedings of the National Academy of Sciences of the United States of America
|
June 20, 1995
A paradigm for drug discovery employing encoded combinatorial libraries
J J Burbaum, M H Ohlmeyer, J C Reader, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 18, 2005
Guiding farnesyltransferase inhibitors from an ECLiPS library to the catalytic zinc
Chia-Yu Huang, Tara M Stauffer, Corey L Strickland, et al.
Journal of Combinatorial Chemistry
|
January 11, 2000
A statistical-based approach to assessing the fidelity of combinatorial libraries encoded with electrophoric molecular tags. Development and application of tag decode-assisted single bead LC/MS analysis
R E Dolle, J Guo, L O'Brien, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 22, 2010
Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinases
Thomas P Matthews, Tatiana McHardy, Suki Klair, et al.
Cancers
|
September 10, 2021
Malignant Ascites in Ovarian Cancer: Cellular, Acellular, and Biophysical Determinants of Molecular Characteristics and Therapy Response
Brittany P Rickard, Christina Conrad, Aaron J Sorrin, et al.
Molecular Cancer Therapeutics
|
January 8, 2010
The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106
Michael I Walton, Paul D Eve, Angela Hayes, et al.
Journal of Medicinal Chemistry
|
October 23, 2012
Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors
Michael Lainchbury, Thomas P Matthews, Tatiana McHardy, et al.
Cancers
|
February 15, 2022
Microtentacle Formation in Ovarian Carcinoma
Jocelyn C Reader, Cong Fan, Eleanor Claire-Higgins Ory, et al.
British Journal of Cancer
|
March 4, 2024
Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
Dana M Roque, Eric R Siegel, Natalia Buza, et al.
British Journal of Cancer
|
February 12, 2022
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
Dana M Roque, Eric R Siegel, Natalia Buza, et al.
Page
of 7